CLINICAL PIPELINE
Pharvaris is committed to developing new oral treatments for bradykinin-mediated angioedema (AE-BK). Our pipeline is anchored by deucrictibant, the only orally administered bradykinin B2 receptor antagonist currently in clinical development, to our knowledge.
Molecule
Deucrictibant
Indication
HAE On-Demand
HAE Prophylaxis
Deucrictibant extended-release tablet maintains sustained therapeutic exposure over 24 hours2 from day one, allowing for once-daily oral treatment to prevent HAE attacks.
AAE-C1INH
Molecule
Indication
Pre-IND
Phase 1
Phase 2
Phase 3
Registrational
Deucrictibant
Deucrictibant is an investigational oral bradykinin B2 receptor antagonist.
HAE
On-Demand
On-Demand
A strategy to manage bradykinin-mediated angioedema attacks is to treat the symptoms of the swelling attack if and when they occur.
HAE Prophylaxis
A strategy to manage bradykinin-mediated angioedema attacks is to prevent them from occurring through prophylaxis.
AAE-C1INH
Acquired angioedema due to C1 inhibitor deficiency is a type of bradykinin-mediated angioedema.
secondary endpoints met
Phase 3 study
open-label extension study
Phase 3 study
extension study
Expanded Access Program
Publications
Patent Library
1. Lesage A, et al. Front Pharmacol. 2020;19:11:916; 2. Lesage A, et al. Int Immunopharmacol. 2022;105:108523; 3. Pharvaris, Data on file. Company Research 4. Maurer M et al. The Lancet Haematology, 2026; 13, e200-e214; 5. Aygoren-Pursun E et al. Lancet Hematol. 2026; 6. Maurer M, et al. Poster presented at: 2022 HAEi Global Leadership Workshop; Oct 6-9, 2022; Frankfurt, Germany; 7. Cicardi M, et al. N Engl J Med. 2010;363(6):532-541; 8. Maurer M, et al. IOS Study Group. Clin Exp Allergy. 2022;52(9):1048-1058; 9. Lesage A, et al. Presented at: 12th C1 Inhihbitor Deficiency Angioedema Workshop; June 3-6, 2021; virtual; 10. Lesage A, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2020 Annual Meeting; Nov 13-15, 2020; virtual; 11. Maurer M, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting; Feb 24-27, 2023; San Antonio, TX, USA; 12. FIRAZYR (icatibant). US Prescribing information. Takeda; 01/2024; 13. Lesage A, et al. Presented at: International Drug Discovery Science & Technology (IDDST); May 22, 2024; Osaka, Japan; 14. Reshef A, et al. J Allergy Clin Immunol. 2024;154(2):398-411.e1; 15. Busse PJ and Christiansen SC. N Engl J Med. 2020;382(12):1136-1148; 16. Smith TD and Riedl MA. Ann Allergy Asthma Immunol. 2024;133(4):380-390; 17. Pharvaris. Data on file (Single-dose crossover PK study in healthy volunteers (n=14) under fasting conditions); 18. Zhang ZY, et al. Presented at: 14th C1 Inhibitor Deficiency and Angioedema Workshop; May 29-Jun 1, 2025; Budapest, Hungary; 19. Riedl MA, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting; Feb 23-26, 2024; Washington DC, USA; 20. Riedl MA, et al. Presented at: American College of Allergy, Asthma & Immunology (ACAAI); Nov 6-10, 2025; Orlando, FL, USA; 21. Maurer M, et al. Poster presented at: 2022 HAEi Global Leadership Workshop; Oct 6-9, 2022; Frankfurt, Germany; 22. Riedl MA, et al. Presented at: 14th C1 Inhibitor Deficiency and Angioedema Workshop; May 29-Jun 1, 2025; Budapest, Hungary; 23. Zhang ZY, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting; Feb 27 - Mar 2, 2026; Philadelphia, USA; 24. Lesage A et al. Presented at: American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2022, Louisville, KY, USA.